09:29 AM EST, 12/23/2024 (MT Newswires) -- Anavex Life Sciences ( AVXL ) said Monday its marketing authorization application for blarcamesine to potentially treat Alzheimer's disease has been accepted for review by the European Medicines Agency.

The company said its application is supported by the results of a phase 2b/3 trial evaluating blarcamesine's clinical efficacy, it added.

Shares of the company were up more than 4% in recent Monday premarket activity.